Vir Biotechnology may be pushing ahead with its combination therapy in hepatitis D, but it's pausing further development in ...
The Department of Health and Human Services is re-evaluating a $590 million contract for avian influenza mRNA vaccines that ...
Kallyope has slipped out results from a phase 2 trial of its obesity candidates, linking the combination of the two oral ...
Teleflex has announced a plan to split its business into two separate independent companies—and it’s setting up one of its ...
When Silence Therapeutics unveiled its latest zerlasiran phase 2 data at the American Heart Association (AHA) conference in ...
Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...
Even as President Donald Trump wages a very public fight against diversity, equity and inclusion (DEI) initiatives in the ...
AV0328, one of Alopexx’s lead candidates, is a synthetic PNAG vaccine that has completed a phase 1 trial. The biotech is ...
The wearable cardiac monitor and defibrillator developer Kestra Medical Technologies aims to raise about $154 million by ...
Idorsia, which is no stranger to needing to find cash quickly, also said it has raised 150 million Swiss francs ($167 million ...
AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...
With Neurocrine having finally shaken up treatment for a rare genetic hormone disease, Harbour BioMed’s antibody offshoot has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results